These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

826 related items for PubMed ID: 12395148

  • 41. Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy.
    Arai S, Allan C, Streiff M, Hutchins GM, Vogelsang GB, Tsai HM.
    Hematol J; 2001; 2(5):292-9. PubMed ID: 11920264
    [Abstract] [Full Text] [Related]

  • 42. Shear stress and von Willebrand factor in health and disease.
    Tsai HM.
    Semin Thromb Hemost; 2003 Oct; 29(5):479-88. PubMed ID: 14631548
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.
    Manea M, Karpman D.
    Pediatr Nephrol; 2009 Mar; 24(3):447-58. PubMed ID: 18807073
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Pathophysiology of thrombotic thrombocytopenic purpura.
    Tsai HM.
    Int J Hematol; 2010 Jan; 91(1):1-19. PubMed ID: 20058209
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.
    Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B.
    Thromb Haemost; 1999 Jan; 81(1):8-13. PubMed ID: 10348715
    [Abstract] [Full Text] [Related]

  • 58. Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).
    Veyradier A, Lavergne JM, Ribba AS, Obert B, Loirat C, Meyer D, Girma JP.
    J Thromb Haemost; 2004 Mar; 2(3):424-9. PubMed ID: 15009458
    [Abstract] [Full Text] [Related]

  • 59. Thrombotic thrombocytopenic purpura and anti-thrombotic therapy targeted to von Willebrand factor.
    Zhou Z, Dong JF.
    Curr Vasc Pharmacol; 2012 Nov; 10(6):762-6. PubMed ID: 22022775
    [Abstract] [Full Text] [Related]

  • 60. Von Willebrand factor--cleaving protease activity in congenital thrombotic thrombocytopenic purpura.
    Allford SL, Harrison P, Lawrie AS, Liesner R, MacKie IJ, Machin SJ.
    Br J Haematol; 2000 Dec; 111(4):1215-22. PubMed ID: 11167764
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.